Harmony Biosciences Q3 revenue $239.5M (+29% YoY); raises FY2025 guidance to $845-865M

Harmony Biosciences Holdings, Inc.

2025-Q3 EPS reported $2.32 revenue$624,677,000

Q3 net revenue $239.5M (WAKIX), +29% YoY; GAAP EPS $0.87, adjusted EPS $1.08.
Raised 2025 revenue guidance to $845-865M from $820-860M.
Record quarterly patient adds ~500, total ~8,100 average narcolepsy patients.
Cash & investments $778M; generated $106M cash flow in Q3.
Pipeline: pitolisant HD IND filed; Phase 3 narcolepsy/IH starts Q4; orexin-2 agonist first subject Q4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.